In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus hypomethylating agents and future targeted therapy combinations in routine care.

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Primary endpoint more than doubled versus standard induction chemotherapy ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

Panelists emphasize that the approval of menin inhibitors has transformed the treatment landscape for KMT2A-rearranged acute myeloid leukemia (AML) by replacing historically limited and toxic ...